Novan Therapeutics Expands Leadership Team With Vice President Of Regulatory Affairs

2/26/2015 11:51:11 AM

Novan Therapeutics, a clinical stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, today announced that Kevin Barber, Ph.D., has been appointed to the newly created position of Vice President of Regulatory Affairs, effective immediately. Dr. Barber will direct Novan's regulatory strategy as the primary interface with the FDA and will report directly to Dr. Nathan Stasko, Novan's President.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.